ASTRAZENECA – A PRESENT AND LONGTIME WILLWORK CLIENT – HAS JUST FINISHED UP A STANDOUT AND CHAMPIONSHIP YEAR, AND CARRIES STRONG AND POSITIVE MOMENTUM INTO 2020

“Science has the power to change the world for the better.  In our industry, we are lucky that we are sometimes able to that we are sometimes able to translate our sciences into medicines that can transform the lives of millions of patients.”

MENE PANGALOS, AstraZeneca Executive Vice President of BioPharmaceuticals Research and Development, speaking in a video that AstraZeneca created on the occasion of and to tell the news of Mr. Panagalos being knighted by Her Majesty Queen Elizabeth II for his contributions to United Kingdom science.  The honor was bestowed as a component of Her Majesty’s 2020 Honours List

(Header image: AstraZeneca R&D Centre and Global Headquarters in Cambridge, UNITED KINGDOM; image credit: AstraZeneca.)

AstraZeneca, based in England, is one of the leading international pharmaceutical corporations.

The company was formed in 1999 with the merger of Swedish Astra AB and the English Zeneca Group.

For several years it has been the privilege of Willwork Global Event Services to provide tradeshow and event services to AstraZeneca.

Accordingly, and most appropriately, Willwork enthusiastically highlights and spreads the word of the winning performance of AstraZeneca in 2019 – a performance that continues into 2020 with increased strength and growing momentum.

Of course, this success and achievement means, for those afflicted and suffering from serious illness, longer and improved quality of life, and hope.

****

On the second-to-last day of 2019, the U.S. Food and Drug Administration (FDA) announced that it approved, to treat pancreatic cancer, a drug co-developed by AstraZeneca and Merck.

The medication – LYNPARZA® – already effective in the treatment of other types of cancer, is in the drug class PARP inhibitors.

Please click here to be taken to a story, “FDA Approves AstraZeneca and Merck’s Lynpraza for pancreatic cancer,” written by Alex Keown, and published in BioSpace, a digital media outlet covering the life sciences industry.

This news came 10 days after the FDA approved ENHERTU® – a medicine AstraZeneca developed in collaboration with Japanese drug maker Daiichi Sankyo – to treat inoperable and metastatic breast cancers.

Clicking here transports you to the FDA announcement of its approval of ENHERTU®.

AstraZeneca has long been involved in the battle to take down breast cancer.

Almost 50 years ago, AstraZeneca produced the first drug to treat the disease. 

Today the company has six breast cancer drugs available, and nine breast cancer drugs in the development pipeline. 

As well, AstraZeneca has played a broader role in the quest to defeat and find a cure for breast cancer. 

AstraZeneca was one of the founders of Breast Cancer Awareness Month, as we detailed in the post, “Willwork Global Event Services Clients are Leading in Breast Cancer Prevention, Diagnosis, Treatment … and the Quest to Find the Cure,”, published on this blog on October 31.

Now, consider that even before the FDA approved LYNPARZA® and ENHERTU®, 2019 had been a championship year for AstraZeneca.

Indeed, three days prior to the FDA releasing its ENHERTU® news, BioPharma Dive – a newsletter and website that covers the biotech and pharma industries, and which has a reader and viewer base of seven million – published a story in which it named AstraZeneca “Pharma of the Year.”  

This recognition continues a run of positive results for AstraZeneca that commenced in 2012 when Pascal Soriot came on board as CEO of the company.    

The following excerpt from the BioPharma Dive story, which is authored by Jonathan Gardner, presents and frames a perspective that takes in Mr. Soriot’s arrival at AstraZeneca and the seven-year stretch that brings us to the fourth quarter of 2019:

“This year, five of AstraZeneca’s blockbusters are growing, while in 2012 five of its seven were in retreat, taking $4.4 billion from its top line.  The company can now confidently point to growing sales, with revenue $2.2 billion greater over the first nine months of the year versus the same period in 2018.”

Please click here to be taken to the complete BioPharma Dive article.

****

You know it has been a good year for an organization when the monarch of the United Kingdom, Her Majesty Queen Elizabeth IIknights one of its employees.

Below we share the first paragraph of an article, “AstraZeneca scientist knighted,” published in The Pharma Letter on the final day of 2019:

“Mene Pangalos … one of the leaders behind AstraZeneca’s (LSE: AZN) remarkable recent record of successful drug development, has been awarded a knighthood.”

Mene Pangalos is the Executive Vice President of BioPharmaceuticals Research and Development at AstraZeneca.

Sir Mene Pangalos, Executive Vice President of Research and Development at AstraZeneca (image credit: The Pharma Letter)

Mr. Pangalos – who is now, by virtue of being knighted, Sir Pangalos – received from Queen Elizabeth II the award and distinction as a component of the 2020 edition of New Year Honours, a UK institution which goes back to 1890, and by which or in the name of the monarch of England, or the vice-regal representative of the monarch, honors are bestowed for contributions and service to the UK.

Willwork Global Event Services recommends an AstraZenca video – which can be accessed by clicking here – in which Sir Pangalos expresses his gratitude and appreciation for the honor of knighthood.

In the video, Sir Pangalos also gives thanks for having a job and a career that he loves and which fulfills him, with these benefits – as he explains – provided through the work goals he pursues, the extraordinary people with whom he collaborates, and the teams and team environment of which he is a member.

Sir Pangalos knows he is part of a great group doing among the most important work on earth. 

Willwork Global Event Services looks forward to continuing to support and provide services for this great group – the great group AstraZeneca.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *